Release
📈 Stocks
—
📊 Neutral
Congruence Therapeutics Reports CGX-195 Reduces Polymerized Z-A1AT Levels
(42 minutes ago)
Congruence Therapeutics confirms CGX-195 efficacy in preclinical trials, demonstrating a significant reduction in polymerized Z-A1AT and improved protein secretion in PiZ mouse…